The Experts below are selected from a list of 6018 Experts worldwide ranked by ideXlab platform

Frederic Jaisser - One of the best experts on this subject based on the ideXlab platform.

  • short and long term administration of the non steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome related cardio renal dysfunction
    Diabetes Obesity and Metabolism, 2018
    Co-Authors: Marianne Lachaux, Peter Kolkhof, Jonatan Barrerachimal, Lionel Nicol, Isabelle Remyjouet, Sylvanie Renet, Anais Dumesnil, Didier Wecker, Vincent Richard, Frederic Jaisser
    Abstract:

    Aim: To determine whether non-steroidal mineralocorticoid receptor (MR) antagonists oppose metabolic syndrome-related end-organ, i.e. cardiac, damage. Materials and methods: In Zucker fa/fa rats, a rat model of metabolic syndrome, we assessed the effects of the non-steroidal MR antagonist finerenone (oral 2 mg/kg/day) on left ventricular (LV) function, haemodynamics and remodelling (using echocardiography, magnetic resonance imaging and biochemical methods). Results: Long-term (90 days) finerenone modified neither systolic blood pressure nor heart rate, but reduced LV end-diastolic pressure and LV end-diastolic pressure-volume relationship, without modifying LV end-systolic pressure and LV end-systolic pressure-volume relationship. Simultaneously , long-term finerenone reduced both LV systolic and diastolic diameters, associated with reductions in LV weight and LV collagen density, while proteinuria and renal nGAL expression were reduced. Short-term (7 days) finerenone improved LV haemodynamics and reduced LV systolic diameter, without modifying LV diastolic diameter. Moreover, short-term finerenone increased myocardial tissue perfusion and reduced myocardial reactive oxygen species, while plasma nitrite levels, an indicator of nitric oxide (NO) bio-availability, were increased. Conclusions: In rats with metabolic syndrome, the non-steroidal MR antagonist finerenone opposed metabolic syndrome-related diastolic cardiac dysfunction and nephropathy. This involved acute effects, such as improved myocardial perfusion, reduced oxidative stress/ increased NO bioavailability, as well as long-term effects, such as modifications in the myocar-dial structure. K E Y W O R D S Animal Pharmacology, cardiovascular disease, diabetes complications, drug development, experimental Pharmacology, type 2 diabetes

Marianne Lachaux - One of the best experts on this subject based on the ideXlab platform.

  • short and long term administration of the non steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome related cardio renal dysfunction
    Diabetes Obesity and Metabolism, 2018
    Co-Authors: Marianne Lachaux, Peter Kolkhof, Jonatan Barrerachimal, Lionel Nicol, Isabelle Remyjouet, Sylvanie Renet, Anais Dumesnil, Didier Wecker, Vincent Richard, Frederic Jaisser
    Abstract:

    Aim: To determine whether non-steroidal mineralocorticoid receptor (MR) antagonists oppose metabolic syndrome-related end-organ, i.e. cardiac, damage. Materials and methods: In Zucker fa/fa rats, a rat model of metabolic syndrome, we assessed the effects of the non-steroidal MR antagonist finerenone (oral 2 mg/kg/day) on left ventricular (LV) function, haemodynamics and remodelling (using echocardiography, magnetic resonance imaging and biochemical methods). Results: Long-term (90 days) finerenone modified neither systolic blood pressure nor heart rate, but reduced LV end-diastolic pressure and LV end-diastolic pressure-volume relationship, without modifying LV end-systolic pressure and LV end-systolic pressure-volume relationship. Simultaneously , long-term finerenone reduced both LV systolic and diastolic diameters, associated with reductions in LV weight and LV collagen density, while proteinuria and renal nGAL expression were reduced. Short-term (7 days) finerenone improved LV haemodynamics and reduced LV systolic diameter, without modifying LV diastolic diameter. Moreover, short-term finerenone increased myocardial tissue perfusion and reduced myocardial reactive oxygen species, while plasma nitrite levels, an indicator of nitric oxide (NO) bio-availability, were increased. Conclusions: In rats with metabolic syndrome, the non-steroidal MR antagonist finerenone opposed metabolic syndrome-related diastolic cardiac dysfunction and nephropathy. This involved acute effects, such as improved myocardial perfusion, reduced oxidative stress/ increased NO bioavailability, as well as long-term effects, such as modifications in the myocar-dial structure. K E Y W O R D S Animal Pharmacology, cardiovascular disease, diabetes complications, drug development, experimental Pharmacology, type 2 diabetes

Peter Kolkhof - One of the best experts on this subject based on the ideXlab platform.

  • short and long term administration of the non steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome related cardio renal dysfunction
    Diabetes Obesity and Metabolism, 2018
    Co-Authors: Marianne Lachaux, Peter Kolkhof, Jonatan Barrerachimal, Lionel Nicol, Isabelle Remyjouet, Sylvanie Renet, Anais Dumesnil, Didier Wecker, Vincent Richard, Frederic Jaisser
    Abstract:

    Aim: To determine whether non-steroidal mineralocorticoid receptor (MR) antagonists oppose metabolic syndrome-related end-organ, i.e. cardiac, damage. Materials and methods: In Zucker fa/fa rats, a rat model of metabolic syndrome, we assessed the effects of the non-steroidal MR antagonist finerenone (oral 2 mg/kg/day) on left ventricular (LV) function, haemodynamics and remodelling (using echocardiography, magnetic resonance imaging and biochemical methods). Results: Long-term (90 days) finerenone modified neither systolic blood pressure nor heart rate, but reduced LV end-diastolic pressure and LV end-diastolic pressure-volume relationship, without modifying LV end-systolic pressure and LV end-systolic pressure-volume relationship. Simultaneously , long-term finerenone reduced both LV systolic and diastolic diameters, associated with reductions in LV weight and LV collagen density, while proteinuria and renal nGAL expression were reduced. Short-term (7 days) finerenone improved LV haemodynamics and reduced LV systolic diameter, without modifying LV diastolic diameter. Moreover, short-term finerenone increased myocardial tissue perfusion and reduced myocardial reactive oxygen species, while plasma nitrite levels, an indicator of nitric oxide (NO) bio-availability, were increased. Conclusions: In rats with metabolic syndrome, the non-steroidal MR antagonist finerenone opposed metabolic syndrome-related diastolic cardiac dysfunction and nephropathy. This involved acute effects, such as improved myocardial perfusion, reduced oxidative stress/ increased NO bioavailability, as well as long-term effects, such as modifications in the myocar-dial structure. K E Y W O R D S Animal Pharmacology, cardiovascular disease, diabetes complications, drug development, experimental Pharmacology, type 2 diabetes

Jonatan Barrerachimal - One of the best experts on this subject based on the ideXlab platform.

  • short and long term administration of the non steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome related cardio renal dysfunction
    Diabetes Obesity and Metabolism, 2018
    Co-Authors: Marianne Lachaux, Peter Kolkhof, Jonatan Barrerachimal, Lionel Nicol, Isabelle Remyjouet, Sylvanie Renet, Anais Dumesnil, Didier Wecker, Vincent Richard, Frederic Jaisser
    Abstract:

    Aim: To determine whether non-steroidal mineralocorticoid receptor (MR) antagonists oppose metabolic syndrome-related end-organ, i.e. cardiac, damage. Materials and methods: In Zucker fa/fa rats, a rat model of metabolic syndrome, we assessed the effects of the non-steroidal MR antagonist finerenone (oral 2 mg/kg/day) on left ventricular (LV) function, haemodynamics and remodelling (using echocardiography, magnetic resonance imaging and biochemical methods). Results: Long-term (90 days) finerenone modified neither systolic blood pressure nor heart rate, but reduced LV end-diastolic pressure and LV end-diastolic pressure-volume relationship, without modifying LV end-systolic pressure and LV end-systolic pressure-volume relationship. Simultaneously , long-term finerenone reduced both LV systolic and diastolic diameters, associated with reductions in LV weight and LV collagen density, while proteinuria and renal nGAL expression were reduced. Short-term (7 days) finerenone improved LV haemodynamics and reduced LV systolic diameter, without modifying LV diastolic diameter. Moreover, short-term finerenone increased myocardial tissue perfusion and reduced myocardial reactive oxygen species, while plasma nitrite levels, an indicator of nitric oxide (NO) bio-availability, were increased. Conclusions: In rats with metabolic syndrome, the non-steroidal MR antagonist finerenone opposed metabolic syndrome-related diastolic cardiac dysfunction and nephropathy. This involved acute effects, such as improved myocardial perfusion, reduced oxidative stress/ increased NO bioavailability, as well as long-term effects, such as modifications in the myocar-dial structure. K E Y W O R D S Animal Pharmacology, cardiovascular disease, diabetes complications, drug development, experimental Pharmacology, type 2 diabetes

Lionel Nicol - One of the best experts on this subject based on the ideXlab platform.

  • short and long term administration of the non steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome related cardio renal dysfunction
    Diabetes Obesity and Metabolism, 2018
    Co-Authors: Marianne Lachaux, Peter Kolkhof, Jonatan Barrerachimal, Lionel Nicol, Isabelle Remyjouet, Sylvanie Renet, Anais Dumesnil, Didier Wecker, Vincent Richard, Frederic Jaisser
    Abstract:

    Aim: To determine whether non-steroidal mineralocorticoid receptor (MR) antagonists oppose metabolic syndrome-related end-organ, i.e. cardiac, damage. Materials and methods: In Zucker fa/fa rats, a rat model of metabolic syndrome, we assessed the effects of the non-steroidal MR antagonist finerenone (oral 2 mg/kg/day) on left ventricular (LV) function, haemodynamics and remodelling (using echocardiography, magnetic resonance imaging and biochemical methods). Results: Long-term (90 days) finerenone modified neither systolic blood pressure nor heart rate, but reduced LV end-diastolic pressure and LV end-diastolic pressure-volume relationship, without modifying LV end-systolic pressure and LV end-systolic pressure-volume relationship. Simultaneously , long-term finerenone reduced both LV systolic and diastolic diameters, associated with reductions in LV weight and LV collagen density, while proteinuria and renal nGAL expression were reduced. Short-term (7 days) finerenone improved LV haemodynamics and reduced LV systolic diameter, without modifying LV diastolic diameter. Moreover, short-term finerenone increased myocardial tissue perfusion and reduced myocardial reactive oxygen species, while plasma nitrite levels, an indicator of nitric oxide (NO) bio-availability, were increased. Conclusions: In rats with metabolic syndrome, the non-steroidal MR antagonist finerenone opposed metabolic syndrome-related diastolic cardiac dysfunction and nephropathy. This involved acute effects, such as improved myocardial perfusion, reduced oxidative stress/ increased NO bioavailability, as well as long-term effects, such as modifications in the myocar-dial structure. K E Y W O R D S Animal Pharmacology, cardiovascular disease, diabetes complications, drug development, experimental Pharmacology, type 2 diabetes